PUBLISHER: The Business Research Company | PRODUCT CODE: 1948391
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948391
Urinary tract obstruction (UTO) treatment devices are medical tools designed to manage blockages that hinder the normal flow of urine from the kidneys to the bladder. These devices help remove obstructions, drain urine, or assist in the healing process, relieving pressure and preventing further damage to the kidneys, bladder, and urinary tract.
The primary types of UTO treatment devices include urinary catheters, ureteroscopes, shock wave lithotripters, laser therapy systems, and others. Urinary catheters are flexible tubes inserted into the bladder to drain urine, helping manage urinary obstructions and preventing complications such as bladder overdistension. These devices are used in a variety of applications, including treating cancers, stones, benign prostatic hyperplasia (BPH), and hydronephrosis, and are utilized by various end users such as hospitals, ambulatory surgical centers, surgical centers, and other healthcare facilities.
Tariffs have increased the cost of imported lasers, endoscopic components, catheters, and precision medical materials used in urinary tract obstruction treatment devices, raising overall equipment and device prices. These impacts are most pronounced in laser therapy systems, digital ureteroscopes, and advanced catheter segments, particularly in Asia-Pacific and Europe where component sourcing is highly globalized. Higher costs have affected procurement by hospitals and surgical centers. However, tariffs have also encouraged local manufacturing and assembly of urology devices, supporting regional supply chains and improving long term cost stability.
The urinary tract obstruction treatment devices market research report is one of a series of new reports from The Business Research Company that provides urinary tract obstruction treatment devices market statistics, including urinary tract obstruction treatment devices industry global market size, regional shares, competitors with a urinary tract obstruction treatment devices market share, detailed urinary tract obstruction treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the urinary tract obstruction treatment devices industry. This urinary tract obstruction treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urinary tract obstruction treatment devices market size has grown strongly in recent years. It will grow from $1.4 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rise in kidney stone prevalence, aging population growth, BPH incidence increase, hospital urology expansion, catheterization procedure growth.
The urinary tract obstruction treatment devices market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to laser-based urology adoption, outpatient obstruction treatments, advanced stent biomaterials, robotic-assisted urology procedures, reduced hospital stay initiatives. Major trends in the forecast period include minimally invasive obstruction management, advanced laser lithotripsy systems, improved ureteral stent designs, endoscopic stone removal techniques, faster post-procedure recovery solutions.
The growing incidence of kidney disease is projected to drive the expansion of the urinary tract obstruction treatment devices market. Kidney disease refers to conditions that impair the kidneys' ability to filter waste and excess fluids from the blood. This rise in kidney disease is linked to factors such as an aging population, higher rates of diabetes and hypertension, and poor lifestyle choices. As kidney disease progresses, urinary tract obstructions become more frequent, creating a demand for devices that help manage these blockages and prevent further kidney damage. For example, a report from Kidney Research UK, published in June 2023, revealed that about 7.2 million people in the UK currently suffer from chronic kidney disease, which makes up over 10% of the population. Of these, 3.25 million are in the advanced stages, while 3.9 million are in earlier stages. By 2033, the number of people with chronic kidney disease is expected to reach 7.61 million. Consequently, the rising prevalence of kidney disease is anticipated to drive market growth in urinary tract obstruction treatment devices.
Major companies operating in the urinary tract obstruction treatment devices market are increasingly concentrating on minimally invasive, retrievable prostatic implants to deliver reversible, outpatient solutions that alleviate obstruction while preserving tissue integrity and function. A retrievable prostatic stent is a small, implantable nitinol device that is placed cystoscopically in the prostatic urethra to restore urinary flow without the need for surgery and can be removed or replaced when necessary. For example, in April 2025, Rivermark Medical, a US-based medical device company, initiated the pivotal RAPID-III trial for the FloStent system, a minimally invasive nitinol prostatic implant developed to relieve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) as a first-line, reversible outpatient treatment. The FloStent system is intended to provide an alternative to pharmacological therapy and more invasive surgical interventions by gently expanding the prostatic urethra to enhance urinary flow. The trial is expected to generate key clinical evidence regarding safety, durability, and improvements in patient quality of life, thereby supporting wider adoption of this implant-based approach for BPH management.
In October 2023, Laborie Medical Technologies Corp., a US-based diagnostic and therapeutic medical technology company, acquired Urotronic, Inc. for up to US$600 million. Through this acquisition, Laborie Medical Technologies seeks to enhance its presence in the urinary tract obstruction treatment devices market by expanding its interventional urology portfolio and accelerating the global adoption of the Optilume drug-coated balloon technology as a minimally invasive treatment option for obstructive lower urinary tract conditions, including urethral strictures and benign prostatic hyperplasia (BPH). Urotronic, Inc. is a US-based medical device company that developed the Optilume drug-coated balloon platform for the treatment of urethral strictures and benign prostatic hyperplasia.
Major companies operating in the urinary tract obstruction treatment devices market are Medtronic Plc, Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Coloplast Corporation, Smiths Group plc, Bio-Rad Laboratories, Teleflex Incorporated, Paul Hartmann AG, Karl Storz SE & Co. KG, Cook Medical, Hollister Incorporated, Amsino International Inc., Richard Wolf GmbH, Braun Melsungen AG, Angiplast Pvt. Ltd., Mais India Medical Devices Pvt. Ltd., Convatec Inc., VYGON (UK) LTD., United Endoscopy, Advin Health Care, Manish Medi Innovation, MicroPort Urocare (Jiaxing) Co. Ltd., Nikotech Pvt Ltd.
North America was the largest region in the urinary tract obstruction treatment devices market in 2025. The regions covered in the urinary tract obstruction treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the urinary tract obstruction treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The urinary tract obstruction (UTO) treatment devices market consists of sales of ureteral stents, nephrostomy tubes, suprapubic catheters, and percutaneous nephrostomy kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Urinary Tract Obstruction Treatment Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses urinary tract obstruction treatment devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for urinary tract obstruction treatment devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The urinary tract obstruction treatment devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.